Switch theme
Sign up to access all valuation multiples
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. The company is engaged in the development, manufacture, and commercialization of high-quality biologics in China and around the world. It focuses on areas such as oncology, metabolism, autoimmunity, metabolism, and ophthalmology. Geographically company's revenue is generated from customers located in Mainland China.
2013
760
LTM Revenue $119M
LTM EBITDA $25.6M
$876M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Boan Biotech has a last 12-month revenue (LTM) of $119M and a last 12-month EBITDA of $25.6M.
In the most recent fiscal year, Boan Biotech achieved revenue of $92.7M and an EBITDA of $22.8M.
Boan Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Boan Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $119M | XXX | $92.7M | XXX | XXX | XXX |
| Gross Profit | $90.0M | XXX | $69.3M | XXX | XXX | XXX |
| Gross Margin | 76% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | $25.6M | XXX | $22.8M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 25% | XXX | XXX | XXX |
| EBIT | $14.9M | XXX | $13.3M | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $14.2M | XXX | $9.3M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $61.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Boan Biotech's stock price is HKD 12 (or $2).
Boan Biotech has current market cap of HKD 6.3B (or $809M), and EV of HKD 6.9B (or $876M).
See Boan Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $876M | $809M | XXX | XXX | XXX | XXX | $0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Boan Biotech has market cap of $809M and EV of $876M.
Boan Biotech's trades at 9.5x EV/Revenue multiple, and 38.4x EV/EBITDA.
Equity research analysts estimate Boan Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Boan Biotech has a P/E ratio of 62.0x.
See valuation multiples for Boan Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $809M | XXX | $809M | XXX | XXX | XXX |
| EV (current) | $876M | XXX | $876M | XXX | XXX | XXX |
| EV/Revenue | 8.0x | XXX | 9.5x | XXX | XXX | XXX |
| EV/EBITDA | 37.3x | XXX | 38.4x | XXX | XXX | XXX |
| EV/EBIT | 64.0x | XXX | 65.7x | XXX | XXX | XXX |
| EV/Gross Profit | 10.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 62.0x | XXX | 86.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -14.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBoan Biotech's last 12 month revenue growth is 24%
Boan Biotech's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Boan Biotech's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Boan Biotech's rule of X is 82% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Boan Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 24% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 53% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 21% | XXX | 49% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 82% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 39% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 60% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Boan Biotech acquired XXX companies to date.
Last acquisition by Boan Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Boan Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Boan Biotech founded? | Boan Biotech was founded in 2013. |
| Where is Boan Biotech headquartered? | Boan Biotech is headquartered in Hong Kong. |
| How many employees does Boan Biotech have? | As of today, Boan Biotech has 760 employees. |
| Who is the CEO of Boan Biotech? | Boan Biotech's CEO is Ms. Hua Jiang. |
| Is Boan Biotech publicy listed? | Yes, Boan Biotech is a public company listed on HKG. |
| What is the stock symbol of Boan Biotech? | Boan Biotech trades under 06955 ticker. |
| When did Boan Biotech go public? | Boan Biotech went public in 2022. |
| Who are competitors of Boan Biotech? | Similar companies to Boan Biotech include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Boan Biotech? | Boan Biotech's current market cap is $809M |
| What is the current revenue of Boan Biotech? | Boan Biotech's last 12 months revenue is $119M. |
| What is the current revenue growth of Boan Biotech? | Boan Biotech revenue growth (NTM/LTM) is 24%. |
| What is the current EV/Revenue multiple of Boan Biotech? | Current revenue multiple of Boan Biotech is 8.0x. |
| Is Boan Biotech profitable? | Yes, Boan Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Boan Biotech? | Boan Biotech's last 12 months EBITDA is $25.6M. |
| What is Boan Biotech's EBITDA margin? | Boan Biotech's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Boan Biotech? | Current EBITDA multiple of Boan Biotech is 37.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
